"Here’s how it would work: a drug would be tested in the neoadjuvant (before-surgery) setting among patients with early-stage cancer. Study participants would receive standard chemotherapy alone or in combination with the investigational drug. The response to these treatments would be assessed at the time of breast cancer surgery. If the addition of the investigational drug produces higher pCR rates than chemotherapy alone, the drug may be considered for accelerated approval." FDA Seeks to Speed Drug Development for Early-Stage, Triple-Negative Breast Cancer(Click to read full story)
